We’ve all got to start somewhere. We recognise that one of the best ways to ensure the continued growth and success of the UK life science sector is to provide an encouraging and supportive environment within which our very early-stage ventures can stress test their science and business ideas. A good cohort isn’t just about great science – it’s about people, making connections and a shared bond centred around wanting to make a difference. For this reason, our cohorts are always a diverse group with a range of different life and work experience. The 2023/2024 cohort was no exception! Meet them here…
Aila Biotech harnesses a patented gene delivery technology to drive the production of immune-regulating biologics at the site of disease.
BugBiome offers a revolutionary solution to the age-old problem of mosquito bites.
CytoCalx is seeking to generate a biomarker to estimate risk and severity of chronic kidney, and cardiovascular, diseases.
Gigabiome aims to develop novel, innovative strategies to address antimicrobial resistance.
At Matrix Bio, our mission is to enable life science research and development from discovery through clinical introduction by providing scientists with unprecedented control over cell culture in 3D.
Neurothread aims to diagnose Parkinson’s disease early via an in vitro diagnostic based on a novel method of characterising new protein biomarkers apparent in many neurodegenerative diseases.